Liver enzymes were elevated upon PLX5622 treatment, consistent with clinical studies using CSF1R inhibitors in cancer patients [41, 42], most likely as a consequence of decreased liver enzyme clearance by Kupffer cells [43]. This evidence concerns the gene CSF1R and cancer.